Southern Research’s Post

The FY2024 House National Defense Authorization Act (NDAA) is a bill of significant importance, and its implications for WuXi and the US biotech landscape are worth noting. According to CEO Rick Connell, "We're reading the context of the bill, and it's all about human genome sequencing data. We genuinely did not understand why we were inserted into the bill." It appears that Congress knows more about WuXi than their CEO! Let's delve into this together and read this article to learn more about the bill's impact on WuXi and the implications for the US biotechnology landscape. #FY2024 #NationalDefenseAuthorizationAct #WuXi #biotech #genomesequencing

Legislation seeking to rein in Chinese CDMOs and genomics companies represents one of the most pressing issues facing biotechs in the U.S. -- in particular small biotechs. BioCentury Inc. conducted a survey of biotech executives and investors to find out what they think of the legislation and the Biotechnology Innovation Organization's recent U-turn to support the #BiosecureAct and other bills -- and how they think the bill will impact their business. We found: * An overwhelming majority of biotechs expect pipeline setbacks * A majority believe replacing WuXi AppTec and WuXi Biologics will be extremely difficult * Many oppose BIO's reversal “It’s hard to know where the hammer will fall next — if WuXi then no company in China is risk-free,” said one person. Said another: “It’s bad policy to try to exclude competition. Which countries will be next?” Read BioCentury Editor in Chief Simone Fishburn's analysis of the survey results: https://lnkd.in/gZgfFjdx (no paywall)

WHERE DID WUXI GO? Interesting “spin” by COX Enterprises! BGI thrown under the bus. Phone calls must have worked! Axios has employed a very deft fig leaf, “….. and the supply chains to do it.” Genomic data is only the science.... scale up and manufacturing capability is critical and why the restrictions on China will be much broader. #china #pharmaceuticals #biologics #manufacturing #decoupling #CDMO #CMO #wuxibiologics #wuxiapptec #BGI #congress #axios https://lnkd.in/e-jk8vSY

A data bottleneck slowed high-throughput screening at a biopharma. With TetraScience, data searches now take minutes instead of days, and hit selection occurs in days instead of weeks. The upshot is faster drug discovery. Download the case study to learn more: https://lnkd.in/eJBY49Ys

Diving into the dynamic world of pharma—where hurdles meet resilience and breakthroughs shape the future of healthcare. In the face of challenges, pharma emerges as a beacon of progress. Breakthroughs are not just scientific milestones; they're victories for humanity. Let's celebrate the dedication of those pioneering innovations in healthcare. 🔍 Challenges: 1️⃣ High R&D Costs: Pharma battles soaring development expenses, posing challenges for innovation.  2️⃣ Regulatory Hurdles: Stringent requirements can delay life-saving treatments' approval. 3️⃣ Supply Chain Complexities: The pandemic exposed vulnerabilities, urging global resilience. 4️⃣ Access Barriers: Equitable medicine access faces hurdles of affordability and distribution. 🚀 Breakthroughs: 1️⃣ mRNA Vaccines: Pfizer and Moderna redefine vaccines, transforming the pandemic fight.  2️⃣ Precision Medicine: Roche and Novartis pioneer tailored therapies based on genetic profiles.  3️⃣ AI in Drug Discovery: Atomwise and BenevolentAI accelerate candidate identification, streamlining R&D.  4️⃣ Collaboration Wave: Pharma unites for shared knowledge, addressing global health challenges.   💬 Join the Conversation: What challenges do you foresee in pharma's future, and which breakthroughs inspire you most? Share your thoughts and continue the transformative dialogue in the pharmaceutical sector. Alok Srivastava Abhishek Srivastava Shubhangi Bansal Arjun Srivastava #PharmaChallenges #MedicalBreakthroughs #InnovationInHealthcare #PharmaceuticalIndustry #FutureOfMedicine

The FT Live US Pharma & Biotech Summit is the top gathering of #biopharma leaders, regulators, investors, and scientists to share unique insights about the year ahead and discuss the most important trends affecting the industry, and the country. See the list of companies that are attending: https://bit.ly/44kazUu   Can you afford to miss out? https://bit.ly/49yZNKO #FTPharma Endpoints News

✨Generative AI is poised to transform nearly every aspect of the life sciences industry – but success at scale hinges on a clear gen AI strategy, dedicated budget, and custom solutions. Together, with my McKinsey colleagues Oscar Viyuela Garcia, Ph.D., Ashley van Heteren, Sherin Ijaz, Nicholas Mills and Rukhshana Motiwala, we surveyed more than 100 pharmaceutical, biotech, and medical-device leaders to better understand their activity related to commercial applications of gen AI. Here are 4 insights we uncovered: ☑ At-scale adoption remains limited ☑ The early impact is promising ☑ Purposeful prioritization is a major differentiator ☑ Companies plan to build their own gen AI capabilities The biggest takeaway of all? Commercial life sciences leaders with a defined gen AI strategy and dedicated budgets were twice as likely to see meaningful results than those without them. Learn more here: https://lnkd.in/d7VQDzvr #commerciallifesciences #lifesciences #genAI #innovation

A data bottleneck slowed high-throughput screening at a biopharma. With TetraScience, data searches now take minutes instead of days, and hit selection occurs in days instead of weeks. The upshot is faster drug discovery. Download the case study to learn more: https://lnkd.in/dqS2-UN6

🔬💼 Exciting Times in Biopharma! 💼🔬 The convergence of Big Tech and Biopharma is a topic that's been making waves in our industry. As technology giants delve into the world of life sciences, it could lead to transformative changes in drug development and healthcare. 📰 Check out this insightful article on BioSpace discussing how Big Tech's entry into biopharma could disrupt the industry. It's a must-read for anyone interested in the future of healthcare and innovation. https://lnkd.in/g3JFdAPF What are your thoughts on this exciting development? Let's discuss in the comments below! 👇 #Biopharma #BigTech #Innovation #Healthcare

GenAI is revolutionizing life sciences, accelerating drug discovery and personalizing medicine. Citizen developers are key in this innovation. Explore how AI governance can align initiatives with your goals and standards, ensuring compliance while developing cutting-edge AI solutions. Read more here: https://bit.ly/4ddHC0m #lifesciences #GenAI #AIgovernance #pharma #biotech #whitepaper #innovation